Intas Biopharmaceuticals

The Biologics Business Unit (BU) of Intas Pharmaceuticals Limited was formerly an independent biotechnology company and was known as Intas Biopharmaceuticals Ltd. Intas Pharmaceuticals limited is an Indian company headquartered in Ahmedabad, India. The Biologics BU is located in Moraiya, Ahmedabad and is one of the leading biosimilar product manufacturers in Asia.

Intas Pharmaceuticals - Biologics Business Unit
Limited
IndustryBiotechnology
Founded1984
HeadquartersAhmedabad, India
ProductsNeukine (GCSF), Erykine (EPO), Intalfa (IFN), Pegasta (Peg GCSF), Terifrac (Teriparatide), Mabtas (Rituximab), Folisurge (FSH)
Number of employees
8000
Websitewww.intaspharma.com

The Biologics BU of Intas Pharmaceuticals has biopharmaceutical operations with R&D facility and an EU-GMP certified bio-pharmaceutical manufacturing facility.[1]

History

Intas Biopharmaceuticals Limited was set up in 1980 by Dr Urmish Chudgar, a leading hematooncologist, as an independent biotechnology division of Intas Pharmaceuticals Ltd. It is a mid-sized generic formulation manufacturer located in Ahmedabad, India. The division was merged with the parent company Intas Pharmaceuticals Limited in 2013. Now, Intas Biopharmaceuticals is headed by Mr. Hasmukh Chudgar.

Corporate headquarters and production site of Intas Biopharmaceuticals Ltd.

The company faced an EU-GMP (Good Manufacturing Practice) audit in December 2006, to seek approval for a clinical trial of its biosimilar Filgrastim in Europe and was certified as EU-GMP compliant in April 2007, becoming the first company in India to receive such certification.

Apart from EU-GMP certification, the company has approvals from MCC South Africa, Gulf Cooperation Council (GCC), Syria, Yemen, Belarus and several other national health authorities for its manufacturing facility and products.

In 2015, the company launched Accofil, a treatment for immune system disorders.[2][3] In 2016, Intas acquired the assets of Teva Pharmaceuticals in the UK and Ireland for $764 million.[4][5]

In 2017, the company announced acquisition of Actavis UK Ltd. & Actavis Ireland Ltd from Teva Pharmaceutical Industries Ltd, for an enterprise value of GBP 603 million.[6]

Intas Biosimilar development timeline
MabTas is Rituximab biosimilar of Intas
Intas manufactured Filgrastim registered in EU


gollark: It doesn't know your coords, it has a vague idea of them from a GeoIP database I hooked up.
gollark: I see. How does it work? What does it do?
gollark: XTHNet?
gollark: https://osmarks.tk/random-stuff/info and 12918 other services.
gollark: And many CC servers provide their own stuff in `_G`.

References
  1. "Intas mfg unit gets EU-GMP certification". The Economic Times. 13 June 2007.
  2. "Intas Pharma launches its first biosimilar product Accofil in Europe". 23 February 2015. Retrieved 25 April 2019 – via The Economic Times.
  3. Reporter, B. S. (23 February 2015). "Ahmedabad-based Intas Pharma launches biosimilar in EU". Retrieved 25 April 2019 – via Business Standard.
  4. Dandekar, Vikas; Barman, Arijit (6 October 2016). "Intas buys Teva's UK & Ireland assets for $764 million to break into global top 20 generic players club". The Economic Times. Retrieved 8 May 2020.
  5. Dandekar, Vikas; Barman, Arijit (7 October 2016). "Chudgars of Intas: A family that dreams big together". Retrieved 25 April 2019 – via The Economic Times.
  6. "Intas Pharmaceuticals Completes Deal to Acquire Actavis". Moneycontrol. Retrieved 8 May 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.